The Use of LUMIC Prosthesis for the Treatment of Periacetabular Metastases

Guzik, Grzegorz

doi:10.5604/15093492.1193013

Cited by 7 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main aim of periacetabular reconstruction is to achieve a functional hip joint and a stable lower extremity. Guzik 19 reported mean postoperative physical function 65 in the Karnofsky scale in a series of six patients who underwent resection of periacetabular area metastases followed by implantation of a LUMiC® prosthesis. The functional status of the patients with custom‐made implants has varied from 50% to 66.6% in evaluation by MSTS scores in different studies 20‐22 .…”

Section: Discussionmentioning

confidence: 99%

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

Erol

Sofulu

Şirin

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

IntroductionThis study aimed to analyze the midterm outcomes of LUMiC® endoprosthetic reconstruction following periacetabular resection of primary bone sarcomas and carcinoma metastases.Patients and MethodsWe retrospectively reviewed the charts of 21 patients (11 male [52.3%], 10 female [47.6%]; mean age 47 ± 16 years) for whom a LUMiC® endoprosthesis (Implantcast) was used to reconstruct a periacetabular defect after internal hemipelvectomy. The tumor was pathologically diagnosed as Ewing's sarcoma in six (28.5%), chondrosarcoma in 10 (47.6%), and bone metastasis from carcinoma in five (23.8%) patients.ResultsThe median follow‐up of patients was 57.8 months (95% confidence interval: 51.9–63.7). The implant survival rate at 1, 2, and 5 years were 95.2%, 85.7%, and 80.9%, respectively. The overall complication rate was 33.3% (n = 7). Four (19%) complications resulted in reconstruction failure. Total reoperation rate was 28.5% (n = 6). The complications were soft tissue failure/dislocation in two patients, aseptic loosening in one, infection in two, and local recurrence in two. At the time of study, seven patients were alive with no evidence of disease, seven were alive with disease, and seven died of disease. The 5‐year overall survival rate and local recurrence‐free survival rates were 67% and 76%, respectively. The median Musculoskeletal Tumor Society score at final follow‐up was 70% (range: 50%–86.6%).ConclusionWe conclude that LUMiC® endoprosthesis provides good functional outcomes and a durable reconstruct. Even though this reconstruction method presents some complications, it provides a stable pelvis in the management of periacetabular malignant tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

Erol

Sofulu

Şirin

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…This can be achieved using an anti-protrusion acetabular cage with screws placed in an antegrade or retrograde mode[ 42 , 43 ]. When there is extensive bone loss prohibiting the aforementioned technique, the skeletal defect may be bridged using a pelvic prosthesis (usually an ice-coned device) that is docked to the remaining intact pelvic bone, a technique which usually requires adequate bone stock around the posterior iliac bone[ 44 ]. In extreme cases of bone loss, the implant may be inserted in the sacrum.…”

Section: Methods and Outcome Of Surgical Treatmentmentioning

confidence: 99%

Current concepts in the surgical treatment of skeletal metastases

Ehne

Tsagozis

2020

WJO

View full text Add to dashboard Cite

Symptomatic metastatic bone disease affects a large proportion of patients with malignant tumours and significantly impairs patients’ quality of life. There are still controversies regarding both surgical indications and methods, mainly because of the relatively few high-quality studies in this field. Generally, prosthetic reconstruction has been shown to result in fewer implant failures and should be preferred in patients with a good prognosis. Survival estimation tools should be used as part of preoperative planning. Adjuvant treatment, which relies on radiotherapy and inhibition of osteoclast function may also offer symptomatic relief and prevent implant failure. In this review we discuss the epidemiology, indications for surgery, preoperative planning, surgical techniques and adjuvant treatment of metastatic bone disease.

show abstract

“…Aseptic loosening rates reported for LUMiC® ranged between 0% and 10% in the short to medium term follow‐up 15,17,20,21 . No aseptic loosening was encountered in our series after a mean of 28 months of follow‐up, up to 5 years for the longest one.…”

Section: Discussionmentioning

confidence: 49%

“…This allows also for a timely surgical intervention, sparing the patients unnecessary surgical delays and hazards encountered with custom made implants. Four retrospective series in the recent medical literature reviewed the outcomes associated with the LUMiC® implant 15,17,20,21 . They analyzed mainly the mechanical and the infectious complications associated with its usage (Table 3).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

LUMiC® endoprosthesis for pelvic reconstruction: A Canadian experience

Rizkallah

Ferguson

Basile

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives: The LUMiC ® prosthesis was introduced to reduce the mechanical complications encountered with periacetabular reconstruction after pelvic tumor resection. Few have evaluated the outcomes associated with its use.Methods: A retrospective study from five Orthopedic Oncology Canadian centers was conducted. All patients with a LUMiC ® endoprosthesis were included. Their charts were reviewed for surgical and functional outcomes.Results: A total of 16 patients were followed for 28 months (3-60). A total of 12 patients (75%) had a LUMiC ® after a resection of a primary sarcoma. Mean surgical time was 555 min. Four patients (25%) had a two-stages procedure. MSTS score was 60.3 preoperatively and 54.3 postoperatively. Patients got a dual mobility bearing and the silver coated implant was used in 7 patients (43.7%). Five patients (31.3%) underwent capsular reconstruction using a fabric. Silver-coating was not found to reduce infection risk (p = 0.61) and capsuloplasty did not prevent dislocation (p = 0.6). Five patients had peroperative complications (31.3%). Eight patients (50%) had an infection including all four with two-stages surgery. Dislocation occurred in five patients (31.3%) whereas no cases of aseptic loosening were reported. A total of 10 patients (62.5%) needed a reoperation. Conclusion:LUMiC ® endoprosthesis provides low rates of aseptic loosening on medium-term follow-up. Infection and dislocation are common complications but we were unable to show benefits of capsuloplasty and silver-coated implants.

show abstract

The Use of LUMIC Prosthesis for the Treatment of Periacetabular Metastases

Cited by 7 publications

References 36 publications

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

Current concepts in the surgical treatment of skeletal metastases

LUMiC® endoprosthesis for pelvic reconstruction: A Canadian experience

Contact Info

Product

Resources

About